相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML
Jae Yoon Jeon et al.
INVESTIGATIONAL NEW DRUGS (2020)
FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia
Jun Long et al.
BLOOD (2020)
Tyrosine kinase inhibitors for acute myeloid leukemia: A step toward disease control?
Juan Eduardo Megias-Vericat et al.
BLOOD REVIEWS (2020)
All-trans retinoic acid exerts selective anti-FLT3-ITD acute myeloid leukemia efficacy through downregulating Chk1 kinase
Wenliang Wang et al.
CANCER LETTERS (2020)
FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development
Hitoshi Kiyoi et al.
CANCER SCIENCE (2020)
Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors
Brian A. Lanman et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase
Daniela Angst et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Targeting AML-associated FLT3 mutations with a type I kinase inhibitor
LaQuita M. Jones et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Profile of Quizartinib for the Treatment of Adult Patients with Relapsed/Refractory FLT3-ITD-Positive Acute Myeloid Leukemia: Evidence to Date
Luke Fletcher et al.
CANCER MANAGEMENT AND RESEARCH (2020)
Potent BRD4 inhibitor suppresses cancer cell-macrophage interaction
Mingzhu Yin et al.
NATURE COMMUNICATIONS (2020)
Small-Molecule Fms-like Tyrosine Kinase 3 Inhibitors: An Attractive and Efficient Method for the Treatment of Acute Myeloid Leukemia
Yue Zhong et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Gilteritinib: potent targeting of FLT3 mutations in AML
Mark Levis et al.
BLOOD ADVANCES (2020)
Quizartinib-resistant FLT3-ITD acute myeloid leukemia cells are sensitive to the FLT3-Aurora kinase inhibitor CCT241736
Andrew S. Moore et al.
BLOOD ADVANCES (2020)
Advancing treatment of acute myeloid leukemia: the future of FLT3 inhibitors
Amro Elshoury et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2019)
Hematopoietic niche drives FLT3-ITD acute myeloid leukemia resistance to quizartinib via STAT5-and hypoxia-dependent upregulation of AXL
Pierre-Yves Dumas et al.
HAEMATOLOGICA (2019)
Virtual Screening Identifies Irreversible FMS-like Tyrosine Kinase 3 Inhibitors with Activity toward Resistance-Conferring Mutations
Dennis Bensinger et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK)
Scott H. Watterson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
New Targeted Agents in Acute Myeloid Leukemia: New Hope on the Rise
Stephan R. Bohl et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Identification of Pyrrolo[2,3-d]pyrimidine-Based Derivatives as Potent and Orally Effective Fms-like Tyrosine Receptor Kinase 3 (FLT3) Inhibitors for Treating Acute Myelogenous Leukemia
Xue Yuan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Quizartinib (AC220): a promising option for acute myeloid leukemia
Fang Zhou et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2019)
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
Jorge E. Cortes et al.
LANCET ONCOLOGY (2019)
Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants
Christopher A. Eide et al.
CANCER CELL (2019)
Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia
Taylor M. Weis et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2019)
Overcoming adaptive therapy resistance in AML by targeting immune response pathways
Katelyn Melgar et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Roles of JAK2 in Aging, Inflammation, Hematopoiesis and Malignant Transformation
Florian Perner et al.
CELLS (2019)
Discovery of 4-piperazinyl-2-aminopyrimidine derivatives as dual inhibitors of JAK2 and FLT3
Yingxiu Li et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology
Matthias Gehringer et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Discovery of an Orally Available Janus Kinase 3 Selective Covalent Inhibitor
Liyang Shi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Targeting FLT3 mutations in AML: review of current knowledge and evidence
Naval Daver et al.
LEUKEMIA (2019)
Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms
Haijiao Zhang et al.
NATURE COMMUNICATIONS (2019)
Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia
Cornelis M. van Tilburg et al.
CLINICAL EPIGENETICS (2019)
Role of CYP3A4 in bone marrow microenvironment-mediated protection of FLT3/ITD AML from tyrosine kinase inhibitors
Yu-Ting Chang et al.
BLOOD ADVANCES (2019)
Melatonin enhances sorafenib-induced cytotoxicity in FLT3-ITD acute myeloid leukemia cells by redox modification
Tian Tian et al.
THERANOSTICS (2019)
Structure-based design of targeted covalent inhibitors
Richard Lonsdale et al.
CHEMICAL SOCIETY REVIEWS (2018)
Discovery of the selective and efficacious inhibitors of FLT3 mutations
Yanle Zhi et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3-and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia
Yue Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Discovery of N2-(4-Amino-cyclohexyl)-9-cyclopentyl-N6-(4-morpholin-4-ylmethyl-phenyl)-9H-purine-2,6-diamine as a Potent FLT3 Kinase Inhibitor for Acute Myeloid Leukemia with FLT3 Mutations
Tomas Gucky et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
The impact of oral arsenic and all-trans-retinoic acid on coagulopathy in acute promyelocytic leukemia
Hong-Hu Zhu et al.
LEUKEMIA RESEARCH (2018)
Arsenic Trioxide and Sorafenib Induce Synthetic Lethality of FLT3-ITD Acute Myeloid Leukemia Cells
Rui Wang et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Kinase inhibitors: the road ahead
Fleur M. Ferguson et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
Clinical development of CDK4/6 inhibitor for breast cancer
Hiroji Iwata
BREAST CANCER (2018)
Melatonin Can Strengthen the Effect of Retinoic Acid in HL-60 Cells
Olga Krestinina et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance
Dilana Staudt et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Enhancing Antiproliferative Activity and Selectivity of a FLT-3 Inhibitor by Proteolysis Targeting Chimera Conversion
George M. Burslem et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2018)
A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations
Takeshi Yamaura et al.
BLOOD (2018)
Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation
Shivani Kapoor et al.
CLINICAL CANCER RESEARCH (2018)
Cabozantinib Is Well Tolerated in Acute Myeloid Leukemia and Effectively Inhibits the Resistance-Conferring FLT3/Tyrosine Kinase Domain/F691 Mutation
Amir T. Fathi et al.
CANCER (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML
Steven Knapper et al.
BLOOD (2017)
Covalent Modifiers: A Chemical Perspective on the Reactivity of α,β-Unsaturated Carbonyls with Thiols via Hetero-Michael Addition Reactions
Paul A. Jackson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia
B. Xu et al.
LEUKEMIA (2017)
Mechanisms of Resistance to FLT3 Inhibitors and the Role of the Bone Marrow Microenvironment
Gabriel Ghiaur et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2017)
Melatonin, a Full Service Anti-Cancer Agent: Inhibition of Initiation, Progression and Metastasis
Russel J. Reiter et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia
Masamichi Mori et al.
INVESTIGATIONAL NEW DRUGS (2017)
Syk inhibitors in clinical development for hematological malignancies
Delong Liu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Discovery of 1-(4-(4-Amino-3-(4-(2-morpholinoethoxy)-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea (CHMFL-FLT3-213) as a Highly Potent Type II FLT3 Kinase Inhibitor Capable of Overcoming a Variety of FLT3 Kinase Mutants in FLT3-ITD Positive AML
Aoli Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors
Ken A. Brameld et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Discovery of an Inhibitor of the Proteasome Subunit Rpn11
Christian Perez et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Acute Myeloid Leukemia, Version 3.2017
Margaret R. O'Donnell et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions
Maria Larrosa-Garcia et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
R. M. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Crotonoside exhibits selective post-inhibition effect in AML cells via inhibition of FLT3 and HDAC3/6
Yu-Zhi Li et al.
ONCOTARGET (2017)
The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial
Mahesh Swaminathan et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2017)
Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO)
Gabriele Nagel et al.
ANNALS OF HEMATOLOGY (2017)
Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells
Clement Larrue et al.
BLOOD (2016)
The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/ITD acute myeloid leukemia cells
E. Chang et al.
LEUKEMIA (2016)
All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD+ leukemia stem cells in vitro and in vivo
Hayley S. Ma et al.
BLOOD (2016)
FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
Elie Traer et al.
CANCER RESEARCH (2016)
Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers
Gerald Lelais et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Antibody-drug conjugates for cancer therapy
Anish Thomas et al.
LANCET ONCOLOGY (2016)
Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia
Alison R. Walker et al.
LEUKEMIA & LYMPHOMA (2016)
Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML
O. Lindblad et al.
ONCOGENE (2016)
Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells
Fangli Chen et al.
ONCOTARGET (2016)
Activation of protein phosphatase 2A in FLT3+acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors
Amanda M. Smith et al.
ONCOTARGET (2016)
Secondary mutations as mediators of resistance to targeted therapy in leukemia
Naval Daver et al.
BLOOD (2015)
Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia
Hamid Ali Nagi Al-Jamal et al.
BMC CANCER (2015)
Melatonin potentiates cisplatin-induced apoptosis and cell cycle arrest in human lung adenocarcinoma cells
P. Plaimee et al.
CELL PROLIFERATION (2015)
Discovery of (R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia
Xixiang Li et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia
I-K Park et al.
LEUKEMIA (2015)
FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors
C. C. Smith et al.
LEUKEMIA (2015)
Metformin synergistically sensitizes FLT3-ITD-positive acute myeloid leukemia to sorafenib by promoting mTOR-mediated apoptosis and autophagy
Fangfang Wang et al.
LEUKEMIA RESEARCH (2015)
Acute Myeloid Leukemia
Hartmut Doehner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Integration of Hedgehog and mutant FLT3 signaling in myeloid leukemia
Yiting Lim et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Metformin inhibits the proliferation of A431 cells by modulating the PI3K/Akt signaling pathway
Yingshan Liu et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2015)
Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 Gatekeeper F691L Mutation with PLX3397
Catherine C. Smith et al.
CANCER DISCOVERY (2015)
Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia
Alexa S. Green et al.
SCIENCE ADVANCES (2015)
Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis
Naval Daver et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
AMG 925 Is a Dual FLT3/CDK4 Inhibitor with the Potential to Overcome FLT3 Inhibitor Resistance in Acute Myeloid Leukemia
Cong Li et al.
MOLECULAR CANCER THERAPEUTICS (2015)
The aurora kinases in cell cycle and leukemia
B. Goldenson et al.
ONCOGENE (2015)
Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation
Richard F. Schlenk et al.
BLOOD (2014)
Treatment With FLT3 Inhibitor in Patients With FLT3-Mutated Acute Myeloid Leukemia Is Associated With Development of Secondary FLT3-Tyrosine Kinase Domain Mutations
Yesid Alvarado et al.
CANCER (2014)
SYK Is a Critical Regulator of FLT3 in Acute Myeloid Leukemia
Alexandre Puissant et al.
CANCER CELL (2014)
Antagonism of SET Using OP449 Enhances the Efficacy of Tyrosine Kinase Inhibitors and Overcomes Drug Resistance in Myeloid Leukemia
Anupriya Agarwal et al.
CLINICAL CANCER RESEARCH (2014)
Sorafenib plus all-trans retinoic acid for AML patients with FLT3-ITD and NPM1 mutations
Sarah Guenounou et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2014)
Discovery of AMG 925, a FLT3 and CDK4 Dual Kinase Inhibitor with Preferential Affinity for the Activated State of FLT3
Zhihong Li et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Preclinical Evaluation of AMG 925, a FLT3/CDK4 Dual Kinase Inhibitor for Treating Acute Myeloid Leukemia
Kathleen Keegan et al.
MOLECULAR CANCER THERAPEUTICS (2014)
BET Protein Antagonist JQ1 Is Synergistically Lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and Overcomes Resistance to FLT3-TKI in AML Cells Expressing FLT-ITD
Warren Fiskus et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Pim kinases phosphorylate Chk1 and regulate its functions in acute myeloid leukemia
L. L. Yuan et al.
LEUKEMIA (2014)
Targeting CHK1 inhibits cell proliferation in FLT3-ITD positive acute myeloid leukemia
Ling Li Yuan et al.
LEUKEMIA RESEARCH (2014)
Evaluation of the Antitumor Effects of BPR1J-340, a Potent and Selective FLT3 Inhibitor, Alone or in Combination with an HDAC Inhibitor, Vorinostat, in AML Cancer
Wen-Hsing Lin et al.
PLOS ONE (2014)
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation
Farhad Ravandi et al.
BLOOD (2013)
Synergistic Activity of Bortezomib and HDACi in Preclinical Models of B-cell Precursor Acute Lymphoblastic Leukemia via Modulation of p53, PI3K/AKT, and NF-κB
Lorenz Bastian et al.
CLINICAL CANCER RESEARCH (2013)
Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors
A. B. Williams et al.
LEUKEMIA (2013)
Selective Akt Inhibitors Synergize with Tyrosine Kinase Inhibitors and Effectively Override Stroma-Associated Cytoprotection of Mutant FLT3-Positive AML Cells
Ellen Weisberg et al.
PLOS ONE (2013)
Pim-1 Kinase Phosphorylates and Stabilizes 130 kDa FLT3 and Promotes Aberrant STAT5 Signaling in Acute Myeloid Leukemia with FLT3 Internal Tandem Duplication
Karthika Natarajan et al.
PLOS ONE (2013)
Suberoylanilide Hydroxamic Acid Induces Hypersensitivity to Radiation Therapy in Acute Myelogenous Leukemia Cells Expressing Constitutively Active FLT3 Mutants
Xufeng Chen et al.
PLOS ONE (2013)
Diversity of the juxtamembrane and TKD1 mutations (Exons 13-15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data
Susanne Schnittger et al.
GENES CHROMOSOMES & CANCER (2012)
A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy
Michael Luebbert et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Optimization of Imidazo[4,5-b]pyridine-Based Kinase Inhibitors: Identification of a Dual FLT3/Aurora Kinase Inhibitor as an Orally Bioavailable Preclinical Development Candidate for the Treatment of Acute Myeloid Leukemia
Vassilios Bavetsias et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Breakdown of the FLT3-ITD/STAT5 Axis and Synergistic Apoptosis Induction by the Histone Deacetylase Inhibitor Panobinostat and FLT3-Specific Inhibitors
Kristin Pietschmann et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors
E. Weisberg et al.
LEUKEMIA (2012)
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
Catherine C. Smith et al.
NATURE (2012)
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
Li Ding et al.
NATURE (2012)
FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo
Takashi Sato et al.
BLOOD (2011)
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse
Mark Levis et al.
BLOOD (2011)
Expression of p-JAK2 predicts clinical outcome and is a potential molecular target of acute myelogenous leukemia
Takayuki Ikezoe et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications
Shinichiro Takahashi
JOURNAL OF HEMATOLOGY & ONCOLOGY (2011)
PRL-3, a Metastasis Associated Tyrosine Phosphatase, Is Involved in FLT3-ITD Signaling and Implicated in Anti-AML Therapy
Jianbiao Zhou et al.
PLOS ONE (2011)
Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia
S. Hart et al.
BLOOD CANCER JOURNAL (2011)
Ubiquitin conjugase UBCH8 targets active FMS-like tyrosine kinase 3 for proteasomal degradation
M. Buchwald et al.
LEUKEMIA (2010)
A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML
Frank Breitenbuecher et al.
BLOOD (2009)
Alteration of the MT1 melatonin receptor gene and its expression in primary human breast tumors and breast cancer cell lines
Ling Lai et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Identification of Novel Kinase Targets for the Treatment of Estrogen Receptor-Negative Breast Cancer
Corey Speers et al.
CLINICAL CANCER RESEARCH (2009)
Mislocalized Activation of Oncogenic RTKs Switches Downstream Signaling Outcomes
Chunaram Choudhary et al.
MOLECULAR CELL (2009)
MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells
Chie Nishioka et al.
LEUKEMIA RESEARCH (2008)
Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells
Ryan J. O. Dowling et al.
CANCER RESEARCH (2007)
Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia
Lisheng Wang et al.
BLOOD (2007)
Impact of FLT3 mutations and secondary cytogenetic changes on the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with a single agent arsenic trioxide regimen
Vikram Mathews et al.
HAEMATOLOGICA (2007)
Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors
Jeffrey Jie-Lou Liao
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells
Warren Fiskus et al.
BLOOD (2006)
Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia
DL Stirewalt et al.
BLOOD (2006)
Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain
F Heidel et al.
BLOOD (2006)
Cell-based selection of internalizing fully human antagonistic antibodies directed against FLT3 for suppression of leukemia cell growth
B Williams et al.
LEUKEMIA (2005)
AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations
C Choudhary et al.
BLOOD (2005)
Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival
KT Kim et al.
BLOOD (2005)
Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs
MG Mohi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
The structural basis for autoinhibition of FLT3 by the juxtamembrane domain
J Griffith et al.
MOLECULAR CELL (2004)
Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3
P Bali et al.
CLINICAL CANCER RESEARCH (2004)
The role of FLT3 in haematopoietic malignancies
DL Stirewalt et al.
NATURE REVIEWS CANCER (2003)
Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia
FM Abu-Duhier et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies
Y Yamamoto et al.
BLOOD (2001)
Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling
SL Zhang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
分享论文
